A Day Up For Arvinas, Inc.
Arvinas, Inc. (ARVN:NASDAQ) shot up at $74.25, representing a gain of 27.2%. On Mon 14 Dec 20, ARVN:NASDAQ hit a New 2-Week High of $58.38. The stock appeared on our News Catalysts scanner on Tue 15 Dec 20 at 12:21 PM in the 'BIOTECH' category. From Mon 30 Nov 20, the stock recorded 80.00% Up Days and 63.64% Green Days
The stock spiked on Mon 14 Dec 20 at $75 with a volume of 18M+.
About Arvinas, Inc. (ARVN:NASDAQ)
Arvinas Inc, formerly Arvinas Holding Co LLC is a private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary PROTAC protein degraders, or Proteolysis-Targeting Chimera, work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins.
Top 10 Gainers:
- Concord Medical Services Holdings Limited (CCM:NYSE), 179.46%
- Anchiano Therapeutics Ltd (ANCN:NASDAQ), 87.01%
- Prevail Therapeutics Inc. (PRVL:NASDAQ), 82%
- MicroVision, Inc. (MVIS:NASDAQ), 34.5%
- ELYS (ELYS:NASDAQ), 29.03%
- Marathon Patent Group, Inc. (MARA:NASDAQ), 27.62%
- Arvinas, Inc. (ARVN:NASDAQ), 27.18%
- Barnwell Industries, Inc. (BRN:NYSEMKT), 26.66%
- Sensus Healthcare, Inc. (SRTS:NASDAQ), 26.4%
- Solid Biosciences Inc. (SLDB:NASDAQ), 23.38%